The United Kingdom and the United States have finalized a landmark bilateral deal that will keep no levies on British medicine shipments entering the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost spending on drugs through the NHS. This move guarantees that import taxes on these crucial goods will stay at nothing for a timeframe of the next three years.
This agreement comes after recent statements to dramatically increase import taxes on patented drug products, with figures floated as high as double the cost.
"This agreement between the UK reinforces the global environment for innovative medicines and introduces much-needed balance to U.S.–U.K. medicine commerce," an announcement said.
Commercial Importance
Medicines constitute one of the Britain's largest goods shipped to the United States, which is clearly the primary market for major British pharmaceutical firms.
Export figures reveal that in the year to the end of last September, the UK sold medicines totaling over eleven billion pounds to the US. This figure represented 17.4% of British export trade in that period.
"This agreement secures employment, boosts funding and facilitates the UK to emerge as a global hub for biotech and pharma," a minister commented.
Key NHS Changes
The deal entails several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to increase total health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum manufacturers must return to the NHS to control costs will be restricted at fifteen percent. In the past, refunds were more than 20%.
Recent Tensions
The pact comes amid a protracted tension between the sector and the ministers over medicine costs and approval rates.
The disagreement were exacerbated by assertions that US patients were paying significantly more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been paused or scrapped, while multi-billion-dollar expansions have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the past decade.
